What factors drove the changes in Zevra's revenue and profit?

What is the revenue and EPS growth rate for Zevra year over year?

What is Zevra's latest dividend and current dividend yield?

Did Zevra beat or miss consensus estimates last quarter?

What were the key takeaways from Zevra’s earnings call?

What is the market's earnings forecast for Zevra next quarter?

What guidance did Zevra's management provide for the next earnings period?

What does Zevra do and what are its main business segments?

- **Revenue Surge**: 2025 net revenue of $106.5 million, with MIPLYFFA driving 82% of sales. Q4 2025 revenue up 15% YoY.
- **Patient Growth**: 52 new enrollment forms in 2025, 24 in Q4, with 50% adults on therapy. Global EAP expanded to 113 patients.
- **Pipeline Momentum**: Celiprolol Phase III study 35% enrolled; FDA engagement for accelerated development. EMA MAA response due Q2 2026.
- **Financial Strength**: $238.9 million cash; net income of $83.2 million for 2025, reversing prior year loss.

**【CEO Summary Section】**
- **Revenue Growth**: Total net revenue for 2025 was $106.5 million, driven by MIPLYFFA sales of $87.4 million. Q4 2025 revenue was $34.1 million, including $26.4 million from MIPLYFFA.
- **MIPLYFFA Momentum**: 52 prescription enrollment forms in 2025 (24 in Q4), with 161 total enrollments since launch. 50% of patients are adults, reflecting broader applicability.
- **Global Expansion**: EU MAA submission under review; global EAP expanded to 113 patients by end-2025, with new distribution agreements for named patient supply.
- **Strategic Moves**: Headquarters moved to Boston to enhance biotech ecosystem collaboration and talent access.

**【CFO Financial Commentary】**
- **Q4 2025 Financials**: Net income of $12.2 million ($0.20 per share), up from $35.7 million loss in Q4 2024. Operating expenses decreased by $1.5 million YoY to $23 million.
- **Full Year 2025**: Net income of $83.2 million ($1.40 per share), compared to $105.5 million loss in 2024. Cash balance of $238.9 million as of December 31, 2025.
- **Cost Management**: R&D expenses down 53% YoY to $12.7 million; SG&A up 42% YoY to $77.6 million due to commercial investments.

**【Q&A Key Highlights】**
- **Enrollment Trends**: Q4 2025 saw 24 new patient starts, with increasing share of newly diagnosed patients. AI predictive model and GeneDx collaboration driving early diagnosis.
- **EMA Update**: 120-day list of questions submitted; response due within 90-day clock stop period. EMA engagement continues for 2026 approval.
- **Celiprolol Pipeline**: 52 patients enrolled in Phase III DISCOVER study (150 target). FDA Type C meeting planned for regulatory acceleration options.
- **Gross to Net**: Dynamic quarterly variability due to payer mix; no immediate guidance on gross to net ratio evolution.

Zevra Therapeutics, Inc. (ZVRA) Q4 2025 Earnings Call Transcript

- **Miplyf Dominance**: $26.1M Q3 revenue, 137 prescriptions, 66% coverage; European MAA submission progressing.
- **Financial Resilience**: $230M cash, disciplined spending; gross-to-net adjustment resolved.
- **Pipeline Focus**: Celiprolol enrollment 44/150; KP1077 phase II completed; VEDS interim data positive.

**【Management Opening Remarks】**
- Zevra's Vice President of IR, Nicole Ochsner, welcomed participants and highlighted the risks associated with forward-looking statements, emphasizing reliance on SEC filings for material uncertainties.

**【CEO Commentary】**
- **Miplyf Success**: Q3 net revenue of $26.1M, with $22.4M from Miplyf, driven by 8 new prescriptions (total 137) and 66% covered lives. European MAA submission under review, with 92 EAP patients in Europe.
- **Pipeline Focus**: Celiprolol phase III enrollment at 44/150; KP1077 phase II completed; VEDS interim analysis with 1 event.
- **Strategic Shifts**: Scaling back Apruva sales efforts; prioritizing Miplyf and high-impact R&D.

**【CFO Financial Commentary】**
- **Financial Health**: $230.4M cash, $61.3M debt; Q3 net loss $0.5M vs. $33.2M prior year. Gross-to-net adjustment ($1.2M) due to Medicare Part D changes.
- **Cost Management**: Operating expenses down 6.8%; R&D (-7.5%), SG&A up 4.6% for commercial expansion.

**【Q&A Highlights】**
- **Patient Access**: 40% diagnosed patients on therapy; 66% coverage via formulary/exception pathways.
- **Europe Strategy**: Evaluating independent launch vs. collaboration; potential 2026 approval and commercialization.
- **Pipeline Updates**: KP1077 strategic options under review; VEDS interim data positive but event-driven trial ongoing.

Zevra Therapeutics, Inc. (ZVRA) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 revenue of $25.9 million, up 26% QoQ, driven by MIPLYFFA's 129 patient enrollments.
- **Strategic Deals**: $150M PRV sale and MAA submission in Europe expand geographic reach.
- **Financial Strength**: $217.7M cash post-PRV sale, offsetting $58.7M OLPRUVA impairment charge.
- **Pipeline Progress**: 39/150 VEDS trial enrollments; Phase III data expected 2026.
- **Commercial Focus**: MIPLYFFA targeting 33% of diagnosed U.S. NPC patients, with 52% payer coverage.

**【CEO Summary Section】**
- Q2 2025 net revenue reached $25.9 million, driven by MIPLYFFA sales of $21.5 million and a 26% quarter-over-quarter growth in commercial product revenue.
- Completed sale of PRV asset for $150 million, strengthening balance sheet.
- Submitted MAA for arimoclomol in Europe, targeting 1,100 NPC patients.
- MIPLYFFA enrolled 129 patients (7 new in Q2), reaching ~33% of diagnosed U.S. NPC patients.
- Expanded Access Program (EAP) in Europe grew to 89 patients.
- Pipeline progress: 39/150 patients enrolled in Phase III DiSCOVER trial for VEDS.

**【CFO Financial Commentary】**
- GAAP net income: $74.7 million ($1.24 per share), driven by PRV sale and cost control.
- Adjusted net loss: $3.2 million ($0.06 per share), excluding one-time items.
- Recognized $58.7 million noncash impairment charge for OLPRUVA intangible assets.
- Total cash: $217.7 million (up from $68.7 million Q1), supporting strategic initiatives.
- Operating expenses: $24.2 million (up 4.7% YoY), driven by commercial activities and proxy contest costs.

**【Q&A Highlights】**
- **MIPLYFFA Enrollment**: 129 total patients (7 new in Q2), 52% payer coverage, 26% QoQ revenue growth.
- **Europe Strategy**: MAA submission on track; EAP expansion aims to convert 89 patients post-approval.
- **OLPRUVA Challenges**: Slow uptake (1 enrollment Q2), 79% payer coverage, strategic focus on MIPLYFFA.
- **Pipeline Momentum**: Genetic testing initiative boosts VEDS trial enrollment; Phase III data expected in 2026.
- **Retention Rates**: High persistence among EAP converts; early commercial patients show strong adherence.
- **Competitive Landscape**: Authorized generic for UCD leader expected; OLPRUVA's convenience profile positions for post-generic competition.

Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript

- **MIPLYFFA Success**: 122 enrollment forms (13 Q1) exceed expectations, with 38% covered lives and strong reimbursement success.
- **Celiprolol Momentum**: 32 patients enrolled in Phase 3 VEDS trial; genetic testing and targeted outreach to accelerate enrollment.
- **Financial Strength**: $217M cash post-PRV sale, enabling independent execution of strategic priorities.
- **Global Expansion**: European MAA submission for MIPLYFFA and expanded EAP for 85 patients.
- **OLPRUVA Progress**: 28 enrollment forms (5 Q1), targeting adult UCD patients with 78% covered lives.


**【CEO Opening Remarks】**
- Zevra achieved strong progress across its 4 strategic pillars: commercial excellence, pipeline innovation, talent culture, and financial foundation.
- MIPLYFFA launch exceeded internal expectations, with 122 prescription enrollment forms (13 in Q1) and enrollment of over 1/3 of diagnosed NPC patients in the U.S.
- Celiprolol Phase 3 trial for VEDS enrolled 32 patients, with plans to accelerate enrollment through targeted outreach and genetic testing.
- Monetization of a pediatric rare disease PRV added $148.3M to the balance sheet, providing financial flexibility.

**【Josh Schafer - Commercial Update】**
- MIPLYFFA: 38% of covered lives achieved, with successful reimbursement via formulary or medical exception. 122 enrollment forms reflect broad patient and prescriber engagement.
- OLPRUVA: 28 total enrollment forms (5 in Q1), focused on adult and OTC-deficient UCD patients. Refill rates align with EAP experience (5-7 years of treatment).
- Global expansion efforts include European MAA submission for MIPLYFFA and expanded EAP for 85 patients.

**【LaDuane Clifton - Financial Results】**
- Q1 2025 net revenue: $20.4M (MIPLYFFA: $17.1M, OLPRUVA: $0.1M, others: $3.2M).
- Operating expenses: $22.8M (-0.6% YoY), driven by SG&A (+9.6%) for commercial activities and reduced R&D costs.
- Net loss: $3.1M ($0.06/share), improved from $16.6M YoY.
- Cash balance: $68.7M + $148.3M PRV proceeds = $217M, supporting strategic priorities.

**【Q&A Highlights】**
- MIPLYFFA: Majority of 122 enrollment forms are on therapy; 38% covered lives via direct formulary or medical exception. Refill rates match EAP durability.
- Celiprolol: 150-patient Phase 3 trial enrollment strategies include genetic testing and targeted provider outreach. No timeline provided, but enrollment acceleration expected.
- Inventory: Managed to target days on hand, aligning with early launch needs.
- OLPRUVA: 78% covered lives, with refined targeting of adult UCD patients.


Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

- **MIPLYFFA Launch Success**: 109 Q4 enrollments (including all U.S. EAP patients) and $10.1M revenue reflect strong demand for NPC treatment. 
- **European Expansion**: MAA submission planned for H2 2025 to target 1,100 European NPC patients. 
- **Financial Strength**: $150M PRV sale extends cash runway to 2029, supporting pipeline investments. 
- **OLPRUVA Strategy Shift**: Focused on adult onset UCD patients with reimbursement challenges. 
- **Long-Term Potential**: 5-7 year EAP retention rates suggest durable MIPLYFFA adherence.

**【CEO Summary Section】**
- Zevra achieved a transformative 2024 with the FDA approval and successful launch of MIPLYFFA for Niemann-Pick Disease Type C (NPC). In Q4, 109 patient enrollment forms were received, including all active U.S. Expanded Access Program (EAP) participants. 
- The company plans to submit a European Marketing Authorization Application (MAA) for MIPLYFFA in H2 2025, targeting approximately 1,100 NPC patients in Europe. 
- Financial stability was strengthened through debt refinancing and the sale of a Priority Review Voucher (PRV) for $150 million, extending the cash runway to 2029.

**【Commercial Product Updates】**
- **MIPLYFFA**: Early launch momentum exceeded expectations, with Q4 revenue of $10.1 million. The combination therapy with miglustat halted disease progression in 12 months, and 90% of U.S. EAP patients converted to commercial product. 
- **OLPRUVA**: Urea cycle disorder (UCD) treatment saw 4 new Q4 enrollments, but slow adoption due to reimbursement challenges. Strategy shifted to target adult onset patients and expand access via new specialty pharmacy partnerships.

**【Financial Highlights】**
- Q4 2024 net revenue: $12.0 million (up 15x YoY), driven by MIPLYFFA ($10.1M) and OLPRUVA ($0.1M). 
- Full year 2024 net loss: $105.5 million, with cash balance of $75.5 million pre-PRV sale. Post-PRV proceeds of $148.3M will bring total liquidity to $223.8M.

**【Q&A Key Takeaways】**
- **Europe Strategy**: MAA submission expected H2 2025, leveraging long-term data to address EMA concerns. 
- **Reimbursement Progress**: 76% of commercial plans cover OLPRUVA; MIPLYFFA approvals via medical exception exceed 30%. 
- **Patient Retention**: Historical EAP data shows 5-7 year treatment continuity, suggesting strong adherence to MIPLYFFA/miglustat combo.


Zevra Therapeutics (ZVRA)-11 Mar 25-2024 Q4 Earnings call transcript

Zevra Therapeutics (ZVRA)-12 Nov 24-2024 Q3 Earnings call transcript

Zevra Therapeutics (ZVRA)-13 Aug 24-2024 Q2 Earnings call transcript

Zevra Therapeutics (ZVRA)-8 May 24-2024 Q1 Earnings call transcript

- **Strategic Milestones Achieved**: Completed Acer acquisition, resubmitted arimoclomol NDA, and advanced KP1077 Phase II.
- **OLPRUVA Launch Momentum**: 70% reimbursement coverage, early patient retention, and team expansion for commercial readiness.
- **Arimoclomol Regulatory Update**: PDUFA date extended to September 2024, with ADCOM anticipated.
- **KP1077 Positive Data**: Demonstrated safety and efficacy in IH, setting stage for Phase III.
- **Financial Stability**: $67.7M cash on hand, runway to 2026, and no material impact from financial restatement.

**【CEO Summary Section】**
- **Execution of Strategic Priorities**: Completed Acer acquisition, resubmitted arimoclomol NDA, and advanced KP1077 Phase II trial.
- **OLPRUVA Launch Progress**: Launched with a 70% reimbursement rate, Quick Start program, and team targeting 40 UCD centers. Early patient refills indicate positive reception.
- **Arimoclomol Update**: FDA extended PDUFA date to September 21, 2024, with ADCOM likely. Expanded access program continues with nearly 1,000 patient signatures of support.
- **KP1077 Phase II Results**: Demonstrated safety, tolerability, and efficacy in IH, with plans for FDA end-of-phase-II meeting.

**【CFO Financial Commentary】**
- **Q4 2023 Financials**: Revenue $11.2M (includes AZSTARYS milestones and OLPRUVA sales), net loss $19.6M, cash $67.7M.
- **Full Year 2023**: Revenue $27.5M, net loss $46M, cash runway to 2026.
- **Restatement Impact**: Warrant accounting change has no cash impact but affects non-cash fair value adjustments.

**【Q&A Key Highlights】**
- **OLPRUVA Market Position**: Differentiated by taste, portability, and dosing flexibility; anticipate competition from generics in 2024.
- **Arimoclomol ADCOM Preparation**: Focused on real-world data integration and safety profile.
- **KP1077 Development**: Positive safety profile supports Phase III design; no immediate plans for narcolepsy trial.
- **Generic RAVICTI Impact**: Expect authorized generics to enter late 2024, with OLPRUVA positioned for differentiation.

Actual											-1.92	-1.07	-0.54	-0.4	-0.06	-0.08	-0.05	-0.7	-0.19	-0.26	-0.34	-0.15	-0.4	-0.51	-0.4	-0.48	-0.69	-0.67	-0.06	1.21	-0.01	0.19
Forecast											-0.96	-0.67	-0.17	0.225	-0.08	-0.075	-0.055	-0.14	-0.1567	-0.185	-0.2325	-0.31	-0.2975	-0.2683	-0.4667	-0.454	-0.4115	-0.395	-0.1814	2.264	-0.0338	0.0504
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	-59.70%	-217.65%	-277.78%	+25.00%	-6.67%	+9.09%	-400.00%	-21.25%	-40.54%	-46.24%	+51.61%	-34.45%	-90.09%	+14.29%	-5.73%	-67.68%	-69.62%	+66.92%	-46.55%	+70.41%	+276.98%

Actual	--	--	--	--	--	--	--	--	--	--	2.09M	2.40M	12.12M	11.99M	1.97M	2.60M	3.96M	1.30M	2.87M	2.30M	2.88M	8.47M	2.90M	13.20M	3.42M	4.45M	3.69M	12.00M	20.40M	25.88M	26.06M	34.10M
Forecast	--	--	--	--	--	--	--	--	--	--	5.40M	1.96M	2.10M	12.10M	2.15M	2.23M	3.06M	1.75M	3.01M	3.11M	2.66M	3.07M	3.38M	11.73M	3.76M	4.37M	4.87M	8.93M	16.91M	22.56M	26.63M	28.05M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-61.31%	+22.29%	+477.00%	-0.94%	-8.65%	+16.33%	+29.36%	-25.61%	-4.59%	-25.95%	+8.43%	+176.19%	-14.33%	+12.51%	-8.87%	+1.92%	-24.11%	+34.45%	+20.62%	+14.74%	-2.12%	+21.56%

ZVRA

ZVRA fundamentals

ZVRA Q4 2025 Earnings

Earnings Call

You can ask Aime

ZVRA

ZVRA fundamentals

ZVRA Q4 2025 Earnings

Earnings Call

ZVRA Earnings Call Summary for Q4/20254:30 PM on Mar 9, 2026

ZVRA Earnings Call Summary for Q3/20254:30 PM on Nov 5, 2025

ZVRA Earnings Call Summary for Q2/20254:30 PM on Aug 12, 2025

ZVRA Earnings Call Summary for Q1/20254:30 PM on May 13, 2025

ZVRA Earnings Call Summary for Q4/20244:30 PM on Mar 11, 2025

You can ask Aime